Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexpramipexole - Areteia Therapeutics

Next Previous
X
Search
Drug Profile

Dexpramipexole - Areteia Therapeutics

Alternative Names: BIIB-050; KNS-760704; RPPX

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Virginia
  • Developer Areteia Therapeutics; Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
  • Class Amines; Antiasthmatics; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Hypereosinophilic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome

Most Recent Events

  • 09 Jul 2024 Areteia Therapeutics initiated phase II SUSPIRE-1 trial in Asthma (Obstructive airway disorders) in USA (PO) (NCT06533553)
  • 29 Apr 2024 Areteia Therapeutics initiates enrolment in a phase III EXHALE-5 trial for Asthma (In Adolescents, In Adults, In the elderly) in the US (NCT06388889)
  • 03 Aug 2023 Updated efficacy data from the phase II EXHALE-1 trial in Asthma released by Areteia Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top